New pages

19:2019:20, 21 August 2025 Parkinson-plus syndrome (hist | edit) [888 bytes] Aidan (talk | contribs) (Created page with "* Group of neurodegenerative diseases similar to Parkinson disease {| class="wikitable" ! !Lewy-body disease !Multiple system atrophy !Corticobasal degeneration !Progressive supranuclear palsy |- |Epidemiology |Common; 30% of all dementia cases |2 to 5 cases per 100,000, mean onset 54 years |5 to 7 per 100,000, mean onset early 60s |3 to 7 per 100,000 |- |Clinical manifestations |Deficits in attention, cognition, visuospatial function, with visual ha...") Tag: Visual edit

14:5114:51, 20 August 2025 CR:DOI:1c9d23338034a184da12d3bfc6764267 (hist | edit) [538 bytes] Aidan (talk | contribs) (Created page with "{{#scite: |reference=wong2015ca |type=journal-article |title=Canadian Public Health Laboratory Network laboratory Guidelines for the Diagnosis of Neurosyphilis in Canada |author=Tom Wong;Kevin Fonseca;Max A Chernesky;Richard Garceau;Paul N Levett;Bouchra Serhir|+sep=; |journal=Canadian Journal of Infectious Diseases and Medical Microbiology |publisher=Wiley |year=2015 |volume=26 |issue=A |doi=10.1155/2015/167484 |issn=1712-9532;1918-1493|+sep=; |retrieved-fro...")

15:4815:48, 19 August 2025 Fidaxomicin (hist | edit) [602 bytes] Aidan (talk | contribs) (Created page with "* Antibiotics indicated for Clostridioides difficile infection * Standard dose is 200 mg p.o. twice daily for 10 days * Pulse-tapered regimen is 200 mg once daily for 7 days followed by 200 mg fidaxomicin every other day for the remaining 13 dosesCiteRef::skinner2021a * In Ontario, EAP criteria for approval through the telephone request service includes: third or subsequent episode treated with vancomycin within 6 months; treatment failure despite at least 7 days...") Tag: Visual edit

15:4615:46, 18 August 2025 Polatuzumab vedotin (hist | edit) [639 bytes] Aidan (talk | contribs) (Created page with "* Anti-CD79b antibody with a humanized IgG1 monoclonal antibody and monomethyl auristatin E (MMAE, an antimitotic agent) * Indicated for diffuse large B-cell lymphoma * Adverse effects ** Include rash, anorexia, diarrhea, nausea/vomiting, fatigue, myelosuppression and opportunistic infections ** Infusion reactions can occur as late as 24 hours post-infusion ** Tumour lysis syndrome ** Hepatotoxicity, mostly low-grade and reversible ** Serious infections, includin...") Tag: Visual edit